SNM awards $25,000 Mallinckrodt Seed Grant in Molecular Imaging/Nuclear Medicine Research

February 01, 2006

Meixang Yu, Ph.D., of Memphis, Tenn., has been named the first recipient of the SNM/Mallinckrodt Seed Grant in Molecular Imaging/Nuclear Medicine Research.

Yu, an associate professor and the chief positron emission tomography (PET) radiochemist at the University of Tennessee Health Science Center, is doing research on "Molecular Imaging and Biological Evaluation of 124I Avastin Anti-VEGF Antibody: Implications for Cancer Diagnosis and Treatment Response." The competitive grant is designed to assist researchers in conducting new and innovative pilot projects that have potential for future support from foundations, corporations or government agencies. Members of the Education and Research Foundation (ERF) for SNM awarded this grant, funded through a $25,000 donation from Tyco Healthcare/Mallinckrodt.

"Through its grants and awards program, SNM actively promotes funding molecular imaging research, which will lead to a better understanding of disease and the development of life-saving treatments," said SNM President Peter. S. Conti, M.D., Ph.D. "This research project will extend our knowledge of how an existing radiotracer may be eventually used to fight colorectal and lung cancer in humans," added ERF Vice President Robert F. Carretta, M.D.

Yu earned a doctorate in radiological chemistry in 1996 from Peking University and did post-doctoral work at Kuopio University in Finland. She received her bachelor's degree in chemistry in 1990 from Peking University in China and a master's degree in analytical chemistry in 1993 from the China Institute of Atomic Energy. Yu has been involved with PET tracer development for more than 10 years and has experience in PET data processing, including modeling calculation.
-end-
The Education and Research Foundation for SNM has been supporting the molecular imaging/nuclear medicine community since its founding in 1969. The foundation's mission is to advance excellence in health care through education and research in molecular imaging/nuclear medicine by provision of grants and awards. "Providing molecular and nuclear imaging professionals with increased support for cutting-edge research is one of the major priorities of SNM and the foundation," said ERF President Michael D. Devous Sr., Ph.D. "We are thankful that Tyco Healthcare/Mallinckrodt came forward to help us on this venture," he added.

For more information about SNM, the foundation or making a contribution, please contact Kathy Bates, SNM's director of development, via phone at (703) 708-9000, ext. 1028, or via e-mail at kbates@snm.org. Information is posted on SNM's Web site at http://www.snm.org/grants.

About SNM
SNM is an international scientific and professional organization of more than 16,000 members dedicated to promoting the science, technology and practical applications of molecular and nuclear imaging to diagnose, manage and treat diseases in women, men and children. Founded more than 50 years ago, SNM continues to train physicians, technologists, scientists, physicists, chemists and radiopharmacists in state-of-the-art imaging procedures and advances; provide essential resources for health care practitioners and patients; publish the most prominent peer-reviewed resource in the field; sponsor research grants, fellowships and awards; and host the premier annual meeting for medical imaging. SNM members have introduced--and continue to explore--biological and technological innovations in medicine that noninvasively investigate the molecular basis of diseases, benefiting countless generations of patients. SNM is based in Reston, Va.; additional information can be found online at http://www.snm.org.

Society of Nuclear Medicine

Related Molecular Imaging Articles from Brightsurf:

New technique offers higher resolution molecular imaging and analysis
The new approach from Northwestern Engineering could help researchers understand more complicated biomolecular interactions and characterize cells and diseases at the single-molecule level.

Molecular imaging offers insight into therapy outcomes for neuroendocrine tumor patients
A new proof-of-concept study published in the May issue of The Journal of Nuclear Medicine has demonstrated that molecular imaging can be used for identifying early response to 177Lu-DOTATATE treatment in neuroendocrine tumor patients.

Non-invasive imaging method spots cancer at the molecular level
Researchers for the first time have combined a powerful microscopy technique with automated image analysis algorithms to distinguish between healthy and metastatic cancerous tissue without relying on invasive biopsies or the use of a contrast dye.

Molecular imaging suggests smokers may have impaired neuroimmune function
Research presented at the 2019 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNM MI) shows preliminary evidence that tobacco smokers may have reduced neuroimmune function compared with nonsmokers.

Novel noninvasive molecular imaging for monitoring rheumatoid arthritis
A first-in-human Phase 1/Phase II study demonstrates that intravenous administration of the radiopharmaceutical imaging agent technetium-99m (99mTc) tilmanocept promises to be a safe, well-tolerated, noninvasive means of monitoring rheumatoid arthritis disease activity.

Improving molecular imaging using a deep learning approach
Generating comprehensive molecular images of organs and tumors in living organisms can be performed at ultra-fast speed using a new deep learning approach to image reconstruction developed by researchers at Rensselaer Polytechnic Institute.

Nanoplatform developed with three molecular imaging modalities for tumor diagnosis
Nanotechnology and biotechnology are bringing us increasingly closer to personalised cancer treatment.

Study suggests molecular imaging strategy for determining molecular classifications of NSCLC
Recent findings suggest a novel positron emission tomography (PET) imaging approach determining epidermal growth factor receptor (EGFR) mutation status for improved lung cancer patient management.

New imaging technique able to watch molecular dynamics of neurodegenerative diseases
Researchers have developed a fast and practical molecular-scale imaging technique that could let scientists view never-before-seen dynamics of biological processes involved in neurodegenerative diseases such as Alzheimer's disease and multiple sclerosis.

Combined optical and molecular imaging could guide breast-conserving surgery
Breast-conserving surgery is the primary treatment for early-stage breast cancer, but more accurate techniques are needed to assess resection margins during surgery to avoid the need for follow-up surgeries.

Read More: Molecular Imaging News and Molecular Imaging Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.